Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Discovery of novel aromatase inhibitors using a homogeneous time-resolved fluorescence assay.

Ji JZ, Lao KJ, Hu J, Pang T, Jiang ZZ, Yuan HL, Miao JS, Chen X, Ning SS, Xiang H, Guo YM, Yan M, Zhang LY.

Acta Pharmacol Sin. 2014 Aug;35(8):1082-92. doi: 10.1038/aps.2014.53. Epub 2014 Jul 21.

2.

Molecular docking and 3D-QSAR-based virtual screening of flavonoids as potential aromatase inhibitors against estrogen-dependent breast cancer.

Awasthi M, Singh S, Pandey VP, Dwivedi UN.

J Biomol Struct Dyn. 2015;33(4):804-19. doi: 10.1080/07391102.2014.912152. Epub 2014 Apr 28.

PMID:
24702656
3.

New steroidal aromatase inhibitors: suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death.

Cepa M, Correia-da-Silva G, da Silva EJ, Roleira FM, Borges M, Teixeira NA.

BMC Cell Biol. 2008 Jul 24;9:41. doi: 10.1186/1471-2121-9-41.

4.
5.

Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells.

Su B, Chen S.

Bioorg Med Chem Lett. 2009 Dec 1;19(23):6733-5. doi: 10.1016/j.bmcl.2009.09.109. Epub 2009 Oct 3.

6.

A c-Myc activation sensor-based high-throughput drug screening identifies an antineoplastic effect of nitazoxanide.

Fan-Minogue H, Bodapati S, Solow-Cordero D, Fan A, Paulmurugan R, Massoud TF, Felsher DW, Gambhir SS.

Mol Cancer Ther. 2013 Sep;12(9):1896-905. doi: 10.1158/1535-7163.MCT-12-1243. Epub 2013 Jul 3.

7.

Design, synthesis, and structure-activity relationships of azolylmethylpyrroloquinolines as nonsteroidal aromatase inhibitors.

Ferlin MG, Carta D, Bortolozzi R, Ghodsi R, Chimento A, Pezzi V, Moro S, Hanke N, Hartmann RW, Basso G, Viola G.

J Med Chem. 2013 Oct 10;56(19):7536-51. doi: 10.1021/jm400377z. Epub 2013 Sep 27.

PMID:
24025069
8.

HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines.

Greco F, Vicent MJ, Penning NA, Nicholson RI, Duncan R.

J Drug Target. 2005 Sep-Nov;13(8-9):459-70.

PMID:
16332571
9.

Discovery of novel scaffolds for Rho kinase 2 inhibitor through TRFRET-based high throughput screening assay.

Oh KS, Mun J, Cho JE, Lee S, Yi KY, Lim CJ, Lee JS, Park WJ, Lee BH.

Comb Chem High Throughput Screen. 2013 Jan;16(1):37-46.

PMID:
22934984
10.

Structure-based design of potent aromatase inhibitors by high-throughput docking.

Caporuscio F, Rastelli G, Imbriano C, Del Rio A.

J Med Chem. 2011 Jun 23;54(12):4006-17. doi: 10.1021/jm2000689. Epub 2011 May 23.

PMID:
21604760
11.

A fluorescent-based high-throughput screening assay for small molecules that inhibit the interaction of MdmX with p53.

Tsuganezawa K, Nakagawa Y, Kato M, Taruya S, Takahashi F, Endoh M, Utata R, Mori M, Ogawa N, Honma T, Yokoyama S, Hashizume Y, Aoki M, Kasai T, Kigawa T, Kojima H, Okabe T, Nagano T, Tanaka A.

J Biomol Screen. 2013 Feb;18(2):191-8. doi: 10.1177/1087057112460729. Epub 2012 Sep 18.

PMID:
22989451
12.

Molecular modeling evaluation of non-steroidal aromatase inhibitors.

Narayana BL, Pran Kishore D, Balakumar C, Rao KV, Kaur R, Rao AR, Murthy JN, Ravikumar M.

Chem Biol Drug Des. 2012 May;79(5):674-82. doi: 10.1111/j.1747-0285.2011.01277.x. Epub 2012 Feb 23.

PMID:
22129073
13.

A novel anti-tumor inhibitor identified by virtual screen with PLK1 structure and zebrafish assay.

Lu J, Xin S, Meng H, Veldman M, Schoenfeld D, Che C, Yan R, Zhong H, Li S, Lin S.

PLoS One. 2013 Apr 26;8(4):e53317. doi: 10.1371/journal.pone.0053317. Print 2013.

14.
15.

Evaluation of a luciferase-based reporter assay as a screen for inhibitors of estrogen-ERα-induced proliferation of breast cancer cells.

Andruska N, Mao C, Cherian M, Zhang C, Shapiro DJ.

J Biomol Screen. 2012 Aug;17(7):921-32. doi: 10.1177/1087057112442960. Epub 2012 Apr 12.

16.

Molecular docking and QSAR studies of aromatase inhibitor androstenedione derivatives.

Roy PP, Roy K.

J Pharm Pharmacol. 2010 Dec;62(12):1717-28. doi: 10.1111/j.2042-7158.2010.01154.x. Epub 2010 Oct 4.

PMID:
21054398
17.

Computational methods for the design of potent aromatase inhibitors.

Favia AD, Nicolotti O, Stefanachi A, Leonetti F, Carotti A.

Expert Opin Drug Discov. 2013 Apr;8(4):395-409. doi: 10.1517/17460441.2013.768983. Epub 2013 Feb 4. Review.

PMID:
23373669
18.

Impact of Aromatase protein variants and drug interactions in breast cancer: a molecular docking approach.

Setti A, Venugopal Rao V, Priyamvada Devi A, Pawar SC, Naresh B, Kalyan CS.

J Recept Signal Transduct Res. 2012 Aug;32(4):225-9. doi: 10.3109/10799893.2012.693088. Epub 2012 Jun 20.

PMID:
22712891
19.

Combining computational and biochemical studies for a rationale on the anti-aromatase activity of natural polyphenols.

Neves MA, Dinis TC, Colombo G, Sá e Melo ML.

ChemMedChem. 2007 Dec;2(12):1750-62.

PMID:
17910019
20.

Limonoids and their anti-proliferative and anti-aromatase properties in human breast cancer cells.

Kim J, Jayaprakasha GK, Patil BS.

Food Funct. 2013 Feb;4(2):258-65. doi: 10.1039/c2fo30209h.

PMID:
23117440
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk